The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung
Executive Summary
If approved in the US, Samsung Bioepis' adalimumab biosimilar may launch June 30, 2023, five months after the market entry date for Amjevita under Amgen's agreement with AbbVie; the 150-day marketing advantage for the first biosimilar approved suggests a benchmark for future patent litigation settlements.
You may also be interested in...
Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims
Sandoz's request that US FDA remove psoriatic arthritis and plaque psoriasis indications from biosimilar's approved labeling appears aimed at defending against patent infringement claims brought by Amgen, legal experts say.
FDA Warning Letter Calls Attention to Celltrion's 'Poor' Aseptic Practices
FDA warning letter to South Korean manufacturer Celltrion cites an extensive list of problems related to inadequate contamination controls and shows how companies launching biosimilars can be tripped up by GMP compliance problems.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: